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Abstract
The COVID-19 pandemic has caused significant shifts in patient care including a 
steep decline in ambulatory visits and a marked increase in the use of telemedicine. 
Infantile hemangiomas (IH) can require urgent evaluation and risk stratification to 
determine which infants need treatment and which can be managed with continued 
observation. For those requiring treatment, prompt initiation decreases morbidity 
and improves long-term outcomes. The Hemangioma Investigator Group has created 
consensus recommendations for management of IH via telemedicine. FDA/EMA-
approved monitoring guidelines, clinical practice guidelines, and relevant, up-to-date 
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1  | INTRODUC TION
The novel coronavirus (COVID-19) pandemic has drastically altered 
health care delivery including widespread reductions in ambula-
tory visits to minimize exposure to and transmission of COVID-19 
resulting in unprecedented adoption of virtual care via telemedi-
cine platforms. In light of these significant shifts in patient care, the 
Hemangioma Investigator Group (HIG) met with the goal of creating 
consensus recommendations to provide timely care for infants with 
infantile hemangioma (IH) via telehealth. The use of beta-blockers 
in the treatment of IH has revolutionized care, and recent American 
Academy of Pediatrics (AAP) clinical practice guidelines (CPG) em-
phasize that early therapeutic intervention is critical for complicated 
IH to prevent medical complications or permanent disfigurement.1 
In this statement, we review FDA/EMA-approved monitoring guide-
lines, information derived from several clinical practice guidelines, 
and other publications regarding initiation and monitoring of be-
ta-blocker therapy, including newly published information which 
could help inform modification of these practices. We give recom-
mendations to help guide decisions about when telehealth may be 
an alternative to in-office visits, including initiation, dosage changes, 
and continued evaluation for those patients requiring treatment. We 
also provide tools for patient communication in context of telemed-
icine. While these recommendations were prompted by the COVID-
19 pandemic, we recognize that they might be relevant in analogous 
settings where there is a disruption of the normal delivery of medical 
care and potentially in settings with lack of access to practitioners 
with expertise in IH management.
2  | METHODS
The Hemangioma Investigator Group (HIG) met via videoconferenc-
ing on March 22, 2020, and subdivided members into 3 groups: one 
to work on the introduction and discussion, one to create a table 
of inclusion and exclusion criteria for telemedicine use of beta-
blockers, and one to curate available patient-education materials for 
practitioners and parents. Through an iterative process of review of 
these 3 domains, we were able to achieve unanimous consensus re-
garding the content of these recommendations.
2.1 | Risk stratification and timing of therapeutic 
intervention, when needed
The most rapid IH growth occurs between 1 and 3 months of age, 
and there is a “window of opportunity” to treat problematic IHs in 
order to prevent morbidities. Telemedicine has a critical role to play 
in facilitating early evaluation and risk stratification. In areas where 
access to specialists has long been challenging, telemedicine triage 
has the potential to improve care for high-risk IH. Early consulta-
tion ideally by 1 month of age or as soon as high-risk features are 
recognized is warranted. Table 1, from the AAP CPG, delineates risk 
categories of IH and potential associated morbidities.
2.2 | Potential risks associated with beta-
blocker treatment
Oral beta-blockers are the gold standard when systemic treatment 
is indicated for IH and propranolol solution is the only FDA/EMA-
approved treatment. Methods for initiation of oral propranolol 
have evolved over time.2-9 Consensus recommendations prior to 
the FDA/EMA approval in 2014 included the following10: (a) screen-
ing for contraindications to propranolol, (b) performing or obtaining 
documentation of, a recent normal cardiovascular and pulmonary 
history and examination, (c) obtaining key historical data including 
poor feeding, dyspnea, tachypnea, diaphoresis, wheezing, heart 
murmur, or family history of heart block or arrhythmia, and (d) pro-
longed in-office monitoring. The FDA/EMA-approved administra-
tion monitoring recommendations include in-office heart rate (HR) 
and blood pressure (BP) monitoring for 2 hours after the first dose 
of propranolol or for increasing the dose (>0.5 mg/kg/d) for in-
fants 5 weeks of adjusted gestational age or older.10,11 More recent 
consensus statements1,12-14 vary in specific recommendations for 
propranolol initiation. Both Australian and British guidelines13,14 
recommend full-term healthy infants without comorbidities may 
undergo outpatient initiation without in-office monitoring with 
initial doses of 1 mg/kg/d.13,14 Both state that a thorough medical 
history and clinical examination including HR are prerequisites to 
initiation of systemic therapy. A recent study by Puttgen et al15 of 
783 patients with in-office monitoring during medication initiation 
publications regarding initiation and monitoring of beta-blocker therapy were used 
to inform the recommendations. Clinical decision-making guidelines about when tel-
ehealth is an appropriate alternative to in-office visits, including medication initiation, 
dosage changes, and ongoing evaluation, are included. The importance of commu-
nication with caregivers in the context of telemedicine is discussed, and online re-
sources for both hemangioma education and propranolol therapy are provided.
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found no symptomatic bradycardia or hypotension occurred dur-
ing the in-office monitoring and minimal, clinically insignificant 
decrease in HR (mean decrease of 8 to 9 beats per minute). Many 
practitioners have moved away from in-office monitoring for those 
infants of gestationally corrected age of 5 weeks or older with nor-
mal birthweight unless other risk factors exist.
While rare, hypoglycemia, seen primarily with intercurrent ill-
ness or decreased feeding, is a serious potentially life-threatening 
risk,16 other risks include bronchospasm and wheezing, usually in 
the context of a respiratory illness, cold hands and feet, gastroin-
testinal upset, and sleep disturbances. All of these potential adverse 
events require anticipatory guidance of parents, which should still 
be a part of clinical care, whether in person or via telemedicine.
2.3 | Other orally administered beta-blockers and 
topical beta-blockers
Other non-FDA-approved beta-blocking agents, including oral at-
enolol and nadolol, have been used for the treatment of IH with 
several publications supporting their efficacy. However, the group 
was unable to reach consensus recommendation regarding telemed-
icine for initiation of either of these medications. Topical timolol has 
been widely used for treating IH with efficacy reported, particularly 
for small, superficial IH.9,15 Systemic absorption is variable but does 
occur,17,18 suggesting that similar prescreening should be performed 
to assure that infants are healthy and have had a normal cardiovas-
cular and pulmonary examinations, for example, via recent history 
and physical examination (see discussion below).
3  | RECOMMENDATIONS
Our recommendations regarding telemedicine initiation of beta-
blocker therapy are summarized in Table 2 with an accompanying al-
gorithm (Figure 1). They were developed after review of relative and 
absolute contraindications for propranolol, reported adverse events, 
FDA/EMA labeling recommendations, and published guidelines, with 
group consensus. They are made with the goal of supporting practic-
ing clinicians in delivering high-quality care in a dramatically altered 
TA B L E  1   Risk level of IHs of varying types
Risk level Clinical examples and reason(s) for concern
Highest • Large (>5 cm) or segmental facial or scalp:
a. higher risk of airway hemangiomas (if beard area),
b. may be associated with PHACE syndrome,
c. high risk of scarring and/or disfigurement.
• Large or segmental lumbosacral or perineal:
a. may be associated with LUMBAR syndrome,
b. high risk of ulceration and scarring.
•	 Multifocal	IHs	(≥5)	and	abdominal	ultrasonography	reveals	hemangiomas:
a. may be associated with abdominal compartment syndrome, high-output
b. congestive heart failure, and hypothyroidism.
• Periocular IH causing eyelid asymmetry, lid closure or ptosis, proptosis, or other findings with potential impact on visual axis:
a. risk of astigmatism, anisometropia, and amblyopia
High • Large segmental IH on trunk or extremities:
a. risk of scarring and/or disfigurement.
•	 Any	facial	IH	≥	2	cm	(>	1	cm	if	≤	3	mo	of	age):
a. high risk of scarring and/or disfigurement.
• Nasal tip or lip IH even if < 1 cm:
a. high risk of scarring and/or permanent distortion of anatomic landmarks.
• Oral
a. risk of ulceration or bleeding, may interfere with feeding.
• Neck or scalp IH > 2 cm during growth phase:
a. risk of ulceration (neck),
b. risk of ulceration, scarring, and/or hair loss (scalp).
• Breast:
a. risk of permanent changes in breast development (eg, breast asymmetry) or nipple contour.
• Ulcerated hemangioma (any site):
a. risk of severe pain, scarring and/or disfigurement, and bleeding.
Intermediate • Perineal IH (localized) without ulceration:
a. potential for ulceration in this location.
• Trunk of extremity IH > 2 cm especially in growth phase or if abrupt transition from normal to affected skin (ie, ledge effect):
a. risk of scarring and/or disfigurement.
Low • IH < 2 cm on trunk of extremities in areas easily covered by clothing.
• IH on trunk of extremities > 2 cm if gradual transition from normal to affected skin.
Note: (Reprinted with permission from Ref. 1).
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care delivery model. They apply primarily to new patients, but also 
for return patients who are being started on a systemic beta-blocker.
Group 1 patients have characteristics which confer a standard 
risk. These infants can be considered as appropriate candidates for 
telemedicine initiation of oral or topical beta-blocker therapy even 
in the absence of an in-person visit. Group 2 includes patients with 
higher risk characteristics, where the risk-benefit ratio favors in-per-
son visit, not only for propranolol initiation but also to discuss man-
agement, risk of extra-cutaneous disease, and to arrange for imaging 
studies if needed. These characteristics might be considered relative 
or absolute exclusion criteria for initiation of medication via tele-
medicine, particularly systemic beta-blockers, and for these infants, 
telemedicine should be used only in exceptional circumstances.
There was broad consensus that in settings where there are 
not disruptions of ambulatory care delivery, in-person evaluation 
for new patients, particularly young infants, is the best approach. 
Physical examination is more thorough and may provide a more ac-
curate assessment of baseline status including subtle clues (such as 
duskiness) suggestive of impending ulceration, and the presence of 
deeper hemangioma not evident with photographs or video without 
palpation. Other advantages of in-person assessment include more 
accurate assessment of weight, confirmation of respiratory and car-
diovascular status, and the opportunity for face-to-face counseling 
and establishing rapport with families, the latter being particularly 
important for infants who need treatment, since the medications 
used for IH are typically continued for many months or longer.
The most commonly used target doses of propranolol are be-
tween 2 and 3 mg/kg/d divided twice daily with FDA/EMA recom-
mendations for starting with 1 mg/kg/d and increasing weekly by 
1 mg/kg/d to target dose. However in the context of outpatient ini-
tiation via telemedicine, our group unanimously agreed that starting 
with a lower dose of 0.5 mg/kg/d divided twice daily, and increasing 
TA B L E  2   Risk stratification when considering beta-blocker treatment
Group 1 (Standard risk): May consider telemedicine initiation of oral or topical beta-blocker therapya 	as	long	as	infant	does	not	have	additional	
features listed for Group 2
• Adjusted gestational age > 5 wk
• Normal birthweight
• Recent documented weight (within 2 wk)
•	 Normal	cardiovascular	examination	within	previous	4	wk	(including	≥	1	documented	HR	after	nursery	discharge)
• Normal respiratory examination within previous 4 weeks
• Healthy in the 24-48 h prior to scheduled telemedicine visit (especially, no respiratory and gastrointestinal signs and symptoms
• IH pattern and distribution does not confer risk of PHACE or LUMBAR syndrome
• Lack of ulceration or minimal/superficial ulceration
• Caregiver is able to understand instructions and demonstrate comprehension (eg, by repeating instructions provided during visit)
• Multiple IH with normal liver ultrasound and without cutaneous IH conferring risks noted in Group 2
Group 2 (Higher risk): Recommend in-person evaluation unless local circumstances make this impossible prior to initiation of systemic beta-
blocker therapyb 
• Corrected gestational age < 5 wk
• Abnormal cardiovascular examination or investigations OR those who lack documentation of this in the post-natal period
• Medium-to-high risk of PHACE (ie, large segmental facial in segments S1, S3, S4 or scalp IH)
• Medium-to-high risk of LUMBAR syndrome (ie, segmental perineal and/or lumbosacral body IH ± visible associated anatomic abnormalities
• Significant IH ulceration
• Ongoing poor oral feeding or poor weight gain
• IH with symptoms of airway compromise (eg, stridor) or bilateral S3 (beard area IH at high risk for airway IH).
• Known pulmonary disease including ongoing respiratory compromise (eg, dyspnea, frequent wheezing or history of bronchospasm)
• Persistent or ongoing hypoglycemia
• Known or suspected congenital heart disease or suggestive symptoms
a. Known or suspected aortic coarctation
b. History of pathologic heart murmur or abnormal echocardiogram
c. Ongoing diaphoresis
d. Ongoing tachypnea
e. Ongoing tachycardia
f. History of syncope
• Extensive hepatic hemangiomas including those resulting in consumptive hypothyroidism or congestive heart failure
• Known brain malformation
• Family history in first degree relative of:
a. Congenital heart disease
b. Sudden death or arrhythmia
• Maternal history of connective tissue disorder (eg, systemic lupus, Sjogren syndrome, polymyositis, or other)
aIn ordinary circumstances, infants are being seen regularly for well-child visits by primary care providers, who weigh and measure infants and 
perform heart and lung examinations as a standard part of their care. If these examinations are not occurring due to disruptions in healthcare, it 
becomes much more difficult to ascertain whether there is a normal cardiovascular or pulmonary examination, if normal growth is occurring and 
other baseline characteristics. In such cases, decisions about initiating therapy must be done on a case-by-case basis. 
bDuring this pandemic and other unusual circumstances, in-person visits may not be possible in a timely fashion. In these settings, triage and 
management decisions need to be made on a case-by-case basis, ideally in conjunction with relevant specialists as needed (eg, ENT and cardiology). 
     |  5Pediatric
Dermatology
FRIEDEN Et al.
every 3 to 4 days by 0.5 mg/kg/d to the target dose was a preferred 
approach. A minority commented that in a typical standard risk in-
fant, they would consider starting at 1 mg/kg/d divided twice, in-
creasing in 0.5 mg/k/d increments every 3 to 4 days to target dosing.
There was uniform consensus that in most cases, follow-up vis-
its can be performed via telemedicine either via two-way synchro-
nous video or asynchronous store-and-forward photographs with 
telephone counseling as long as it is possible to examine the infant's 
hemangioma adequately and to provide sufficient parental counsel-
ing. Even if video visits are used, having photographs of the IH up-
loaded shortly before a telemedicine visit is often necessary to be 
able to adequate evaluate the IH, given the variability of visualization 
with live-interactive portals.
Clinical situations which may be less optimal for follow-up 
telemedicine visits include diagnostic uncertainty, unexpected IH 
growth, functional impairment, or significant or worsening ulcer-
ation. If there is medication intolerance or lack of efficacy requiring 
consideration of another treatment modality (eg, transition from top-
ical to systemic therapy or addition of another systemic agent), then 
providers should consider whether a telemedicine visit is sufficient 
to address the clinical scenario or if an in-person visit is indicated.
3.1 | Use of topical timolol
Topical timolol is efficacious for smaller, thin IH.17,19,20 Although 
rigorous safety studies have not been performed, if used in small 
amounts, the rate of adverse events is very low.19 Systemic absorp-
tion occurs to varying degrees measurable in both urine and plasma; 
plasma concentrations demonstrated to have measurable systemic 
β-blocking activity in adults have been reported.17,18,21 Based on 
this information, we recommend that timolol application should 
be limited to the dose for which safety data have been most often 
reported, 1 drop twice daily of timolol 0.5%. Timolol is not recom-
mended for the treatment of thick or deep IH, both because it is less 
effective and systemic absorption may be greater.18 Because of the 
potential for systemic exposure of topical application, pre-screening 
should be performed to assure that infants are healthy with normal 
cardiopulmonary examinations via recent history and physical ex-
amination. As with oral beta-blockers, temporary discontinuation is 
recommended if patients experience respiratory or gastrointestinal 
symptoms. Infants under 3 months of age, and those whose history 
suggests ongoing IH growth, should be monitored via frequent visits 
or photographs submitted by parents to assure that therapy does 
F I G U R E  1   Algorithm for management
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not need to be switched from topical to oral. Such follow-up visits 
can often be done via telemedicine.
4  | DISCUSSION
The COVID-19 pandemic has caused an abrupt shift from ambulatory 
visits to telemedicine platforms. This consensus statement provides 
guidance on timely treatment for patients with IH requiring early in-
tervention while prioritizing patient safety. While we acknowledge 
the benefits of in-person visits when health care systems are op-
erating normally, there was group consensus that telehealth visits 
could provide an alternative method of evaluation and treatment as 
long as safeguards are in place to minimize risks. Our recommendations 
are based upon first ensuring that there are no contraindications for 
therapy, documentation of a recent normal physical examination, 
and no signs or symptoms of active illness (Table 2). We suggest that 
these patients are amenable to initiation of therapy through a pro-
cess of limited physical examination coupled with virtual counseling 
and education about the natural history, treatment options, admin-
istration of medication, and potential adverse reactions to therapy.
We recognize that there are other circumstances in which these 
recommendations may be applicable including natural disasters 
(eg, earthquakes, hurricanes). In addition, there are patients whose 
access to specialty care is severely limited due to geographic con-
straints (eg, living many hours away from a center with expertise in 
the evaluation and management of IH) where these recommenda-
tions may prove beneficial.
With or without telemedicine, all patients with IH require care-
ful consideration of risks and benefits of any proposed treatment, 
discussion with families regarding treatment options, and recom-
mendations and information about possible adverse events from 
prescribed medications (Table 3). For IH still in the rapid growth 
phase, we recommend particularly close follow-up, ideally within 
1-2 weeks. Telemedicine is particularly well-suited for these typically 
brief follow-up visits to assure that the IH is behaving as anticipated. 
Parents should be advised to reach out to practitioners in the context 
of changes in the IH (eg, ulceration, ongoing growth, development/
progression of functional impairment). If the patient develops respi-
ratory symptoms (eg, cough, wheezing, respiratory distress), gastro-
intestinal symptoms (eg, vomiting, diarrhea, decreased intake), or 
lethargy, medication should be immediately discontinued and a phy-
sician notified.22 Although infection with COVID-19 in young infants 
and toddlers most often does not result in severe symptoms, it can 
cause symptomatic infection including respiratory illness. Similar to 
other infections which can result in fever or respiratory symptoms, 
we recommend temporarily stopping propranolol in the setting of 
active infant COVID-19 infection until symptoms from the infection 
cease. Comprehensive counseling and communication of potential 
risks and benefits of treatment are of paramount importance both 
for anticipatory guidance and to help minimize side effects. Online 
resources (Table 3) can be very helpful both in reinforcing education 
regarding the diagnosis of IH and specifics of treatment and possible 
side effects.
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TA B L E  3   Online Infantile Hemangioma Resourcesa
General hemangioma information
• https://pedsd erm.net/site/asset s/files /1028/2_spd_infan tile_
heman giomas_web_final.pdf
• https://heman gioma educa tion.org/infan tile-heman gioma s/
• https://en.wikip edia.org/wiki/Infan tile_Heman gioma
• https://www.aap.org/en-us/advoc acy-and-polic y/aap-healt h-initi 
ative s/Infan tile-Heman gioma s/Pages /defau lt.aspx
Beta-blocker therapy information
• https://heman gioma educa tion.org/heman gioma -treat ment/new-
hig-propr anolo l-educa tion-video -for-careg ivers
• https://pedsd erm.net/site/asset s/files /1028/12_spd_propr 
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